Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Dr Andrea Kossler
Stanford University School of Medicine, Palo Alto, CA, USA
Dr Andrea Lora Kossler, MD, FACS, is an associate professor of ophthalmology at Stanford University School of Medicine, director of Oculofacial Plastic and Orbital Surgery at the Byers Eye Institute at Stanford and co-director of the Stanford Multidisciplinary Thyroid Eye Disease Clinic in Palo Alto, CA, USA. read more
Dr Kossler specializes in thyroid eye disease, orbital oncology and orbital surgery. Her research interests include the proteomic evaluation of ocular surface and orbital inflammatory diseases and evaluating targeted therapies for orbital malignancy and thyroid eye disease. Dr Kossler has authored over 100 publications and abstracts and is a national and international speaker on thyroid eye disease and orbital surgery.
Dr Andrea Kossler discloses: Consulting fees from Acelyrin, Amgen, Argenx, Genentech, Immunovant, Kriya, Lassen and Viridian. Grants/research support from Amgen, Kriya, Lassen, Sling and Viridian.
Dr Edsel Ing
University of Alberta, Edmonton and University of Toronto, Ontario, Canada
Dr Edsel Ing, MD, PhD, FRCSC, MPH, MEd, MIAD, MBA is the professor and chair of Ophthalmology and Visual Sciences at the University of Alberta, and a professor of ophthalmology at the University of Toronto in Canada. read more
He specializes in oculoplastics, strabismus and neuro-ophthalmology. Dr Ing completed his medical school and residency at the University of Toronto, and three fellowships at Wills Eye, the Mayo Clinic and Allegheny General Hospital. He received his Master of Public Health from Harvard and his Master of Education from Johns Hopkins. Dr Ing’s PhD thesis focused on an ophthalmic diagnostic prediction model and was completed at Kingston University, UK.
Dr Edsel Ing has no financial interests/relationships or affiliations to disclose in relation to this activity.
Dr Mario Salvi
University of Milan, Milan, Italy
Dr Mario Salvi is head of the Graves’ Orbitopathy Center of the Fondazione IRCCS Cà Granda, Milan, Italy, which he founded in 2003. read more
Throughout his career, Dr Salvi has pioneered immunotherapy, performing clinical studies with rituximab, belimumab, teprotumumab and tocilizumab in Graves’ orbitopathy, in addition to multicentre trials carried out within the 2021 European Group on Graves’ orbitopathy (EUGOGO). Dr Salvi contributed to the book: ‘Graves’ Orbitopathy: A Multidisciplinary Approach’, edited by EUGOGO, and co-authored the American Thyroid Association/European Thyroid Association Consensus Document on Management of Graves’ Orbitopathy. He has published more than 240 papers (h-index 48) and given over 200 scientific communications and invited lectures at international meetings.
Dr Mario Salvi discloses: Advisory board/panel fees from Amgen and IBSA. Consulting fees from Aesara, IBSA, Inmagene, Lycia and Tourmaline. Grants/research support from Immunovant, Roche, Sling and Viridian.
